Cytochrome P450 2C9 Genotype
Also known as: CYP2C9, 2C9
Use
This germline pharmacogenomic test identifies variants in the CYP2C9 gene, a drug‑metabolizing enzyme involved in the metabolism of important medications such as warfarin, phenytoin, siponimod, and certain nonsteroidal anti‑inflammatories, supporting personalized medication selection and dosage adjustments.
Special Instructions
Normal phlebotomy procedure. Physician attestation of informed consent is required if ordering from certain states (AK, DE, FL, GA, IA, MN, NV, NJ, NY, OR, SD, VT) or if performed in MA.
Limitations
The metabolism of drugs is influenced by genotype and other factors. This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics; it has not been cleared or approved by FDA. The assay has been validated pursuant to CLIA regulations.
Methodology
PCR-based (PCR)
Biomarkers
Result Turnaround Time
7-14 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
5 mL (3 mL minimum)
Minimum Volume
3 mL
Container
EDTA (lavender‑top) tube
Collection Instructions
Whole blood collected in EDTA (lavender‑top) tube; also acceptable: ACD solution B (yellow‑top) or sodium heparin (green‑top) tube; normal phlebotomy procedure.
Storage Instructions
Store and ship at room temperature immediately. Do not freeze.
Causes for Rejection
Moderate or gross hemolysis; received frozen
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 8 days |
| Refrigerated | 8 days |
| Frozen | Unacceptable |